RECURRENT PRIMARY PERITONEAL CARCINOMA
Clinical trials for RECURRENT PRIMARY PERITONEAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PRIMARY PERITONEAL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT PRIMARY PERITONEAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Ovarian cancer vaccine shows promise in small safety trial
⭐️ VACCINE ⭐️ CompletedThis early-stage study tested a custom-made vaccine for people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The vaccine was made from each patient's own white blood cells and designed to train the immune system to attack cancer cells. The main goal was to …
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: EARLY_PHASE1 • Sponsor: Mayo Clinic • Aim: ⭐️ VACCINE ⭐️
Last updated May 12, 2026 13:40 UTC
-
New hope for hard-to-treat ovarian cancer: drug combo shows promise in trial
Disease control CompletedThis study tested a new drug, relacorilant, combined with a standard chemotherapy (nab-paclitaxel) in 178 women with ovarian, fallopian tube, or peritoneal cancer that came back and no longer responds to platinum-based chemo. The goal was to see if the combination helps keep the …
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated May 17, 2026 01:08 UTC
-
New combo immunotherapy tackles tough ovarian cancer
Disease control CompletedThis study tested two immunotherapy drugs, durvalumab and tremelimumab, in 100 people with ovarian, fallopian tube, or peritoneal cancer that came back or stopped responding to platinum-based chemo. The goal was to see if giving the drugs together or one after the other works bet…
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Targeted radiation shows promise for recurrent gynecologic cancers
Symptom relief CompletedThis early-phase study tested a precise type of radiation called stereotactic body radiation therapy (SBRT) in 15 women with ovarian or uterine cancer that had come back in a limited area. The goal was to find the safest dose and see how well it controls tumor growth. Researchers…
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Symptom relief
Last updated May 15, 2026 11:56 UTC